Skip to main content

Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.

Publication ,  Conference
Desjardins, A; Peters, KB; Vlahovic, G; Randazzo, D; Boulton, S; Massey, WC; Lipp, ES; Herndon, JE; Healy, P; Miller, E; Karmali, RA; Friedman, HS
Published in: Journal of Clinical Oncology
May 20, 2015

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

2067 / 2067

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Peters, K. B., Vlahovic, G., Randazzo, D., Boulton, S., Massey, W. C., … Friedman, H. S. (2015). Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. In Journal of Clinical Oncology (Vol. 33, pp. 2067–2067). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.2067
Desjardins, Annick, Katherine B. Peters, Gordana Vlahovic, Dina Randazzo, Susan Boulton, Woody C. Massey, Eric S. Lipp, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.” In Journal of Clinical Oncology, 33:2067–2067. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.2067.
Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Massey WC, et al. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2067–2067.
Desjardins, Annick, et al. “Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1.Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. 2067–2067. Crossref, doi:10.1200/jco.2015.33.15_suppl.2067.
Desjardins A, Peters KB, Vlahovic G, Randazzo D, Boulton S, Massey WC, Lipp ES, Herndon JE, Healy P, Miller E, Karmali RA, Friedman HS. Carboxyamidotriazole orotate (CTO) in combination with bevacizumab (BEV) for adult patients with recurrent malignant glioma post-BEV failure: Phase 1. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. 2067–2067.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

2067 / 2067

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences